infract


Also found in: Dictionary, Medical, Legal.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • verb

Synonyms for infract

References in periodicals archive ?
OMT showed infract volume reduction in the brain of mice, which received MCAO and improved the neurological deficit score, neuronal morphology in prefrontal cortex, and hippocampus.
Timely myocardial reperfusion using primary percutaneous coronary intervention (PCI) remains the most effective treatment strategy for limiting infract size, reducing left ventricular remodeling, and improving clinical outcomes following ST-segment elevation myocardial infarction (STEMI).
L-Arginine treated group reduced infract size with compared I/R group which was 30% of total surface area of left (Figure 1 B).
The lipids (cholesterol ester, cholesterol, triglyceride, cerebroside, ceramide, phosphatidylcholine), glutathione and infract volume levels were expressed as mean [+ or -] SEM and compared using One Way ANOVA (spss16.
Coronary collateral development has potential protective roles such as limited infract size, less aneurysm formation in the ventricle wall, improved ventricular function, fewer future cardiovascular events and improved survival in patients with occlusive coronary lesions (7, 8).
Ischemia-reperfusion injury is a major contributor to infract size and therefore plays a significant role in the long-term morbidity and mortality associated with acute myocardial infarction (AMI).
Coronary collateral development has potential protective roles such as limited infract size, less ventricular aneurysm formation, improved ventricular function, fewer future cardiovascular events, and improved survival in patients with occlusive coronary lesions (1-5).
Specifically, the Complaint alleges that unknown to investors and contrary to defendants' representations, the Company's primary product, AngioJet System, a minimally invasive catheter system designed to remove blood clots using a stream of water: (i) was not more effective than competing drug therapies (such as Urokinase, the leading product on the market) or other existing alternatives, and it did not reduce significant procedural complications or significantly increase positive benefits; and (ii) could not be expanded as a "technology platform" because it was not, in the first instance, effective for routine use in a broad range of heart attack patients to reduce the size of infracts.